한글목차

세계의 전사체 시퀀싱 시장 규모는 2024년에 25억 7,111만 달러로 추정되며, 2031년까지 60억 7,262만 달러에 달할 것으로 예측되며, 예측 기간인 2025-2031년에 CAGR 14.17%의 성장이 전망됩니다.

북미의 시장 규모는 2024년에 10억 3,543만 달러로 2031년까지 24억 2,930만 달러에 달할 전망이며, 2025-2031년 예측 기간 동안 CAGR은 14.1%로 예상됩니다.

아시아태평양의 시장 규모는 2024년에 6억 7,421만 달러로 2031년까지 17억 2,486만 달러에 달할 전망이며, 2025-2031년 예측 기간 동안 CAGR은 15.42%로 예상됩니다.

유럽의 시장 규모는 2024년에 8억 213만 달러로 2031년까지 18억 727만 달러에 달할 전망이며, 2025-2031년 예측 기간 동안 CAGR은 13.4%로 예상됩니다.

세계의 전사체 시퀀싱 주요 기업은 Illumina, Thermo Fisher Scientific, Eurofins Scientific, Roche, Bio-Rad, Agilent Technologies, LabCorp, QIAGEN, Pacific Biosciences, Azenta, BGI Genomics, Novogene, Macrogen, Shanghai ZJ Bio-Tech, Tsingke Biotechnology 등입니다. 2024년 세계 주요 5개사가 매출 기준으로 약 66.47%의 점유율을 차지했습니다.

세계의 전사체 시퀀싱 시장에 대해 조사 분석했으며, 각 지역의 시장 규모와 예측, 주요 기업의 순위, 시장 점유율 등의 정보를 제공합니다.

목차

제1장 시장 개요

• 전사체 시퀀싱 제품 소개
• 세계의 전사체 시퀀싱 시장 규모 예측(2020-2031년)
• 전사체 시퀀싱 시장 동향과 성장 촉진요인
  • 전사체 시퀀싱 산업 동향
  • 전사체 시퀀싱 시장 촉진요인과 기회
  • 전사체 시퀀싱 시장 과제
• 가정과 제한
• 조사 목적
• 대상 연도

제2장 경쟁 분석 : 기업별

• 세계의 전사체 시퀀싱 기업 매출 순위(2024년)
• 세계의 전사체 시퀀싱 매출 : 기업별(2020-2025년)
• 주요 기업 전사체 시퀀싱 제조 거점 분포, 본사
• 전사체 시퀀싱 시장 경쟁 분석
  • 전사체 시퀀싱 시장 집중도(2020-2025년)
  • 세계의 전사체 시퀀싱 매출의 5대·10 대기업(2024년)
  • 세계의 주요 기업 : 기업 유형별(Tier 1·Tier 2·Tier 3)(2024년 시점 전사체 시퀀싱 매출 기준)
• 인수합병, 확대

제3장 부문 : 유형별

• 소개 : 유형별
  • 코딩 RNA
  • 논코딩 RNA
• 세계의 전사체 시퀀싱 판매량 : 유형별
  • 세계의 전사체 시퀀싱 판매량 : 유형별(2020년·2024년·2031년)
  • 세계의 전사체 시퀀싱 판매량 : 유형별(2020-2031년)
  • 세계의 전사체 시퀀싱 판매량 : 유형별(2020-2031년)

제4장 부문 : 용도별

• 소개 : 용도별
  • 바이오메디컬 분야
  • 비의학 분야
• 세계의 전사체 시퀀싱 판매량 : 용도별
  • 세계의 전사체 시퀀싱 판매량 : 용도별(2020년·2024년·2031년)
  • 세계의 전사체 시퀀싱 판매량 : 용도별(2020-2031년)
  • 세계의 전사체 시퀀싱 판매량 : 용도별(2020-2031년)

제5장 부문 : 지역별

• 세계의 전사체 시퀀싱 판매량 : 지역별
  • 세계의 전사체 시퀀싱 판매량 : 지역별(2020년·2024년·2031년)
  • 세계의 전사체 시퀀싱 판매량 : 지역별(2020-2025년)
  • 세계의 전사체 시퀀싱 판매량 : 지역별(2026-2031년)
  • 세계의 전사체 시퀀싱 판매량 : 지역별(2020-2031년)
• 북미
  • 북미의 전사체 시퀀싱 판매량(2020-2031년)
  • 북미의 전사체 시퀀싱 판매량 : 국가별(2024년·2031년)
• 유럽
  • 유럽의 전사체 시퀀싱 판매량(2020-2031년)
  • 유럽의 전사체 시퀀싱 판매량 : 국가별(2024년·2031년)
• 아시아태평양
  • 아시아태평양의 전사체 시퀀싱 판매량(2020-2031년)
  • 아시아태평양의 전사체 시퀀싱 판매량 : 지역별(2024년·2031년)
• 남미
  • 남미의 전사체 시퀀싱 판매량(2020-2031년)
  • 남미의 전사체 시퀀싱 판매량 : 국가별(2024년·2031년)
• 중동 및 아프리카
  • 중동 및 아프리카의 전사체 시퀀싱 판매량(2020-2031년)
  • 중동 및 아프리카의 전사체 시퀀싱 판매량 : 국가별(2024년·2031년)

제6장 부문 : 주요 국가/지역별

• 주요 국가/지역 전사체 시퀀싱 판매량 성장 동향(2020년·2024년·2031년)
• 주요 국가/지역 전사체 시퀀싱 판매량(2020-2031년)
• 미국
  • 미국의 전사체 시퀀싱 판매량(2020-2031년)
  • 미국의 전사체 시퀀싱 판매량 : 유형별(2024년·2031년)
  • 미국의 전사체 시퀀싱 판매량 : 용도별(2024년·2031년)
• 유럽
  • 유럽의 전사체 시퀀싱 판매량(2020-2031년)
  • 유럽의 전사체 시퀀싱 판매량 : 유형별(2024년·2031년)
  • 유럽의 전사체 시퀀싱 판매량 : 용도별(2024년·2031년)
• 중국
  • 중국의 전사체 시퀀싱 판매량(2020-2031년)
  • 중국의 전사체 시퀀싱 판매량 : 유형별(2024년·2031년)
  • 중국의 전사체 시퀀싱 판매량 : 용도별(2024년·2031년)
• 일본
  • 일본의 전사체 시퀀싱 판매량(2020-2031년)
  • 일본의 전사체 시퀀싱 판매량 : 유형별(2024년·2031년)
  • 일본의 전사체 시퀀싱 판매량 : 용도별(2024년·2031년)
• 한국
  • 한국의 전사체 시퀀싱 판매량(2020-2031년)
  • 한국의 전사체 시퀀싱 판매량 : 유형별(2024년·2031년)
  • 한국의 전사체 시퀀싱 판매량 : 용도별(2024년·2031년)
• 동남아시아
  • 동남아시아의 전사체 시퀀싱 판매량(2020-2031년)
  • 동남아시아의 전사체 시퀀싱 판매량 : 유형별(2024년·2031년)
  • 동남아시아의 전사체 시퀀싱 판매량 : 용도별(2024년·2031년)
• 인도
  • 인도의 전사체 시퀀싱 판매량(2020-2031년)
  • 인도의 전사체 시퀀싱 판매량 : 유형별(2024년·2031년)
  • 인도의 전사체 시퀀싱 판매량 : 용도별(2024년·2031년)

제7장 기업 개요

• Illumina
• Thermo Fisher Scientific
• Eurofins Scientific
• Roche
• Bio-Rad
• Agilent Technologies
• LabCorp
• QIAGEN
• Pacific Biosciences
• Azenta
• BGI Genomics
• Novogene
• Macrogen
• Shanghai ZJ Bio-Tech
• Tsingke Biotechnology

제8장 산업 체인 분석

• 전사체 시퀀싱 산업 체인
• 전사체 시퀀싱 업스트림 해석
  • 주요 원자재
  • 제조 비용 구조
• 분석 파이프라인
• 다운스트림 분석(고객 분석)
• 판매 모델과 판매 채널

제9장 조사 결과와 결론

제10장 부록

영문목차

The global market for Transcriptome Sequencing was estimated to be worth US$ 2,571.11 million in 2024 and is forecast to a readjusted size of US$ 6,072.62 million by 2031 with a CAGR of 14.17% during the forecast period 2025-2031.

North American market for Transcriptome Sequencing was valued at $ 1,035.43 million in 2024 and will reach $ 2,429.30 million by 2031, at a CAGR of 14.1% during the forecast period of 2025 through 2031.

Asia-Pacific market for Transcriptome Sequencing was valued at $ 674.21 million in 2024 and will reach $ 1,724.86 million by 2031, at a CAGR of 15.42% during the forecast period of 2025 through 2031.

Europe market for Transcriptome Sequencing was valued at $ 802.13 million in 2024 and will reach $ 1,807.27 million by 2031, at a CAGR of 13.4% during the forecast period of 2025 through 2031.

The global key companies of Transcriptome Sequencing include Illumina, Thermo Fisher Scientific, Eurofins Scientific, Roche, Bio-Rad, Agilent Technologies, LabCorp, QIAGEN, Pacific Biosciences, Azenta, BGI Genomics, Novogene, Macrogen, Shanghai ZJ Bio-Tech and Tsingke Biotechnology, etc. In 2024, the global five largest players hold a share approximately 66.47% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Transcriptome Sequencing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Transcriptome Sequencing by region & country, by Type, and by Application.

The Transcriptome Sequencing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transcriptome Sequencing.

Market Segmentation

By Company

• Illumina
• Thermo Fisher Scientific
• Eurofins Scientific
• Roche
• Bio-Rad
• Agilent Technologies
• LabCorp
• QIAGEN
• Pacific Biosciences
• Azenta
• BGI Genomics
• Novogene
• Macrogen
• Shanghai ZJ Bio-Tech
• Tsingke Biotechnology

Segment by Type

• Coding RNA
• Noncoding RNA

Segment by Application

• Biomedical Field
• Non-medical Field

By Region

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia-Pacific
• Europe
• Germany
• France
• U.K.
• Italy
• Nordic Countries
• Rest of Europe
• South America
• Brazil
• Rest of South America
• Middle East & Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Transcriptome Sequencing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Transcriptome Sequencing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Transcriptome Sequencing in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Transcriptome Sequencing Product Introduction
• 1.2 Global Transcriptome Sequencing Market Size Forecast (2020-2031)
• 1.3 Transcriptome Sequencing Market Trends & Drivers
  • 1.3.1 Transcriptome Sequencing Industry Trends
  • 1.3.2 Transcriptome Sequencing Market Drivers & Opportunity
  • 1.3.3 Transcriptome Sequencing Market Challenges
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Transcriptome Sequencing Players Revenue Ranking (2024)
• 2.2 Global Transcriptome Sequencing Revenue by Company (2020-2025)
• 2.3 Key Companies Transcriptome Sequencing Manufacturing Base Distribution and Headquarters
• 2.4 Transcriptome Sequencing Market Competitive Analysis
  • 2.4.1 Transcriptome Sequencing Market Concentration Rate (2020-2025)
  • 2.4.2 Global 5 and 10 Largest Companies by Transcriptome Sequencing Revenue in 2024
  • 2.4.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transcriptome Sequencing as of 2024)
• 2.5 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Coding RNA
  • 3.1.2 Noncoding RNA
• 3.2 Global Transcriptome Sequencing Sales Value by Type
  • 3.2.1 Global Transcriptome Sequencing Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Transcriptome Sequencing Sales Value, by Type (2020-2031)
  • 3.2.3 Global Transcriptome Sequencing Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Biomedical Field
  • 4.1.2 Non-medical Field
• 4.2 Global Transcriptome Sequencing Sales Value by Application
  • 4.2.1 Global Transcriptome Sequencing Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Transcriptome Sequencing Sales Value, by Application (2020-2031)
  • 4.2.3 Global Transcriptome Sequencing Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Transcriptome Sequencing Sales Value by Region
  • 5.1.1 Global Transcriptome Sequencing Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Transcriptome Sequencing Sales Value by Region (2020-2025)
  • 5.1.3 Global Transcriptome Sequencing Sales Value by Region (2026-2031)
  • 5.1.4 Global Transcriptome Sequencing Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Transcriptome Sequencing Sales Value, 2020-2031
  • 5.2.2 North America Transcriptome Sequencing Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Transcriptome Sequencing Sales Value, 2020-2031
  • 5.3.2 Europe Transcriptome Sequencing Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Transcriptome Sequencing Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Transcriptome Sequencing Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Transcriptome Sequencing Sales Value, 2020-2031
  • 5.5.2 South America Transcriptome Sequencing Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Transcriptome Sequencing Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Transcriptome Sequencing Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Transcriptome Sequencing Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Transcriptome Sequencing Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Transcriptome Sequencing Sales Value, 2020-2031
  • 6.3.2 United States Transcriptome Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Transcriptome Sequencing Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Transcriptome Sequencing Sales Value, 2020-2031
  • 6.4.2 Europe Transcriptome Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Transcriptome Sequencing Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Transcriptome Sequencing Sales Value, 2020-2031
  • 6.5.2 China Transcriptome Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Transcriptome Sequencing Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Transcriptome Sequencing Sales Value, 2020-2031
  • 6.6.2 Japan Transcriptome Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Transcriptome Sequencing Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Transcriptome Sequencing Sales Value, 2020-2031
  • 6.7.2 South Korea Transcriptome Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Transcriptome Sequencing Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Transcriptome Sequencing Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Transcriptome Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Transcriptome Sequencing Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Transcriptome Sequencing Sales Value, 2020-2031
  • 6.9.2 India Transcriptome Sequencing Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Transcriptome Sequencing Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Illumina
  • 7.1.1 Illumina Profile
  • 7.1.2 Illumina Main Business
  • 7.1.3 Illumina Transcriptome Sequencing Products, Services and Solutions
  • 7.1.4 Illumina Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Illumina Recent Developments
• 7.2 Thermo Fisher Scientific
  • 7.2.1 Thermo Fisher Scientific Profile
  • 7.2.2 Thermo Fisher Scientific Main Business
  • 7.2.3 Thermo Fisher Scientific Transcriptome Sequencing Products, Services and Solutions
  • 7.2.4 Thermo Fisher Scientific Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Thermo Fisher Scientific Recent Developments
• 7.3 Eurofins Scientific
  • 7.3.1 Eurofins Scientific Profile
  • 7.3.2 Eurofins Scientific Main Business
  • 7.3.3 Eurofins Scientific Transcriptome Sequencing Products, Services and Solutions
  • 7.3.4 Eurofins Scientific Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Eurofins Scientific Recent Developments
• 7.4 Roche
  • 7.4.1 Roche Profile
  • 7.4.2 Roche Main Business
  • 7.4.3 Roche Transcriptome Sequencing Products, Services and Solutions
  • 7.4.4 Roche Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Roche Recent Developments
• 7.5 Bio-Rad
  • 7.5.1 Bio-Rad Profile
  • 7.5.2 Bio-Rad Main Business
  • 7.5.3 Bio-Rad Transcriptome Sequencing Products, Services and Solutions
  • 7.5.4 Bio-Rad Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Bio-Rad Recent Developments
• 7.6 Agilent Technologies
  • 7.6.1 Agilent Technologies Profile
  • 7.6.2 Agilent Technologies Main Business
  • 7.6.3 Agilent Technologies Transcriptome Sequencing Products, Services and Solutions
  • 7.6.4 Agilent Technologies Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Agilent Technologies Recent Developments
• 7.7 LabCorp
  • 7.7.1 LabCorp Profile
  • 7.7.2 LabCorp Main Business
  • 7.7.3 LabCorp Transcriptome Sequencing Products, Services and Solutions
  • 7.7.4 LabCorp Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.7.5 LabCorp Recent Developments
• 7.8 QIAGEN
  • 7.8.1 QIAGEN Profile
  • 7.8.2 QIAGEN Main Business
  • 7.8.3 QIAGEN Transcriptome Sequencing Products, Services and Solutions
  • 7.8.4 QIAGEN Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.8.5 QIAGEN Recent Developments
• 7.9 Pacific Biosciences
  • 7.9.1 Pacific Biosciences Profile
  • 7.9.2 Pacific Biosciences Main Business
  • 7.9.3 Pacific Biosciences Transcriptome Sequencing Products, Services and Solutions
  • 7.9.4 Pacific Biosciences Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Pacific Biosciences Recent Developments
• 7.10 Azenta
  • 7.10.1 Azenta Profile
  • 7.10.2 Azenta Main Business
  • 7.10.3 Azenta Transcriptome Sequencing Products, Services and Solutions
  • 7.10.4 Azenta Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Azenta Recent Developments
• 7.11 BGI Genomics
  • 7.11.1 BGI Genomics Profile
  • 7.11.2 BGI Genomics Main Business
  • 7.11.3 BGI Genomics Transcriptome Sequencing Products, Services and Solutions
  • 7.11.4 BGI Genomics Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.11.5 BGI Genomics Recent Developments
• 7.12 Novogene
  • 7.12.1 Novogene Profile
  • 7.12.2 Novogene Main Business
  • 7.12.3 Novogene Transcriptome Sequencing Products, Services and Solutions
  • 7.12.4 Novogene Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Novogene Recent Developments
• 7.13 Macrogen
  • 7.13.1 Macrogen Profile
  • 7.13.2 Macrogen Main Business
  • 7.13.3 Macrogen Transcriptome Sequencing Products, Services and Solutions
  • 7.13.4 Macrogen Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Macrogen Recent Developments
• 7.14 Shanghai ZJ Bio-Tech
  • 7.14.1 Shanghai ZJ Bio-Tech Profile
  • 7.14.2 Shanghai ZJ Bio-Tech Main Business
  • 7.14.3 Shanghai ZJ Bio-Tech Transcriptome Sequencing Products, Services and Solutions
  • 7.14.4 Shanghai ZJ Bio-Tech Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.14.5 Shanghai ZJ Bio-Tech Recent Developments
• 7.15 Tsingke Biotechnology
  • 7.15.1 Tsingke Biotechnology Profile
  • 7.15.2 Tsingke Biotechnology Main Business
  • 7.15.3 Tsingke Biotechnology Transcriptome Sequencing Products, Services and Solutions
  • 7.15.4 Tsingke Biotechnology Transcriptome Sequencing Revenue (US$ Million) & (2020-2025)
  • 7.15.5 Tsingke Biotechnology Recent Developments

8 Industry Chain Analysis

• 8.1 Transcriptome Sequencing Industrial Chain
• 8.2 Transcriptome Sequencing Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Manufacturing Cost Structure
• 8.3 Analysis Pipeline
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
  • 10.1.2 Data Source
• 10.2 Author Details
• 10.3 Disclaimer